JAOA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


JAOA • Vol 103 • No 7_suppl_3 • July 2003 • 12-17
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chilton, R. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chilton, R. J.

Lipid and Nonlipid Benefits of Statins

Robert J. Chilton, DO

Dr Chilton is director of the Catheterization Laboratory and an associate professor in the Department of Medicine, Division of Cardiology at the University of Texas Health Science Center at San Antonio.

Address correspondence to Robert J. Chilton, DO, FACC, FAHA, FACOI, Associate Professor, Department of Medicine, Division of Cardiology, University of Texas Health Science Center at San Antonio, 27971 Smithson Valley, San Antonio, TX 78261.E-mail: chilton{at}uthscsa.edu

The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) provides an evidence-based approach to the diagnosis of dyslipidemia and the management of low-density lipoprotein cholesterol (LDL-C). This article provides a brief overview of the ATP III therapeutic approach (therapeutic lifestyle changes alone or in combination with a pharmacologic agent) in which the patient's level of risk for coronary heart disease guides the intensity of intervention to lower LDL-C concentrations. Because statins have been found to effectively help patients reach ATP III target LDL-C levels to reduce their risk of coronary events, they tend to be the treatment of choice when initial therapy with therapeutic lifestyle changes alone fails to achieve the target level. Discussion includes a summary of the beneficial properties of statins beyond lipid lowering.




This article has been cited by other articles:


Home page
Arch Intern MedHome page
B. A. Golomb, M. H. Criqui, H. White, and J. E. Dimsdale
Conceptual Foundations of the UCSD Statin Study: A Randomized Controlled Trial Assessing the Impact of Statins on Cognition, Behavior, and Biochemistry
Arch Intern Med, January 26, 2004; 164(2): 153 - 162.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Osteopathic Association.